<div dir="ltr"><p style="color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px;margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em">Prezados (as), muito bom dia!</p><p style="color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px;margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline"></strong></p><p style="color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px;margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em">Espero que estejam todos bem. Conforme solicitado pelo Prof. Sandro Gallo, venho por meio deste convidá-los para o seminário desta sexta-feira (14/08):</p><div><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Seminário Conjunto UFSCar/USP</strong></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Data e Horário:</strong></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px">14/08/2020 às 14h</p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Local:</strong></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px">Google Meet - <a rel="noreferrer noopener" href="https://meet.google.com/mho-xyta-gky?hs=122&authuser=0" target="_blank" style="font-family:Arial,Helvetica,sans-serif;font-size:small">meet.google.com/mho-xyta-gky</a></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Título:</strong></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><span style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Comparison of inferential seamless phase II/III designs for acute stroke trials with biomarkers as surrogate endpoints</span></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Palestrante:</strong></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px">Márcio Augusto Diniz (Cedars-Sinai)</p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Resumo:</strong></p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px">Inferential seamless phase II/III designs have been proposed as an alternative path to<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">traditional drug development in order to decrease failure in large phase III trials. Seamless phase II/III<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">designs allow investigators to accommodate randomized phase II designs that require larger samples<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">sizes instead of single-arm designs that depend on historical data with often different case-mix<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">populations. Response adaptive randomization (RAR) is often implemented aiming to allocate more<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">subjects to the apparently superior arm, stop the lead-in phase early for efficacy, drop a poorly<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">performing arm, and thus, may resulting in more patients being treated successfully. However, RAR<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">algorithms require a short-term response relative to the accrual rate, otherwise, allocation probabilities<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">will not be updated sufficiently quick such that patients could be benefited. Several authors have<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">proposed the use of biomarkers as a surrogate for a long-term endpoint when calculating allocation<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">probabilities without considering their diagnostic performance. In this work, we study the loss in power,<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">type I error and trial duration for an acute stroke trial with a long-term ordinal endpoint as function of<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">sensitivity and specificity for biomarkers that are used as surrogate when calculating allocation<br style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">probabilities and/or stopping rules.</p><p style="margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em;color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px"><strong style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Autores:</strong> Márcio Augusto Diniz, Patrick Lyden and Mourad Tighiouart - Cedars-Sinai Medical Center</p></div><div><p style="color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px;margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em"><span style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Contamos com a presença de todos!</span></p><p style="color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px;margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em"><span style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Lembramos também que todos os seminários e outras atividades previstas encontram-se na página do PIPGEs </span><a href="http://www.pipges.ufscar.br/" target="_blank" style="font-family:Arial,Helvetica,sans-serif;font-size:small">http://www.pipges.ufscar.br/</a></p><p style="color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px;margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em"><span style="margin:0px;padding:0px;list-style:none;vertical-align:baseline">Atenciosamente,</span></p></div><p style="color:rgb(0,0,0);font-family:Roboto,sans-serif;font-size:13.9776px;margin:0px 0px 1em;padding:0px;list-style:none;vertical-align:baseline;line-height:1.8em"><span style="font-family:Arial,Helvetica,sans-serif;font-size:small;color:rgb(34,34,34)">-------</span><br></p><div><div dir="ltr" class="gmail_signature" data-smartmail="gmail_signature"><div dir="ltr"><div dir="ltr"><div dir="ltr"><div dir="ltr"><div>Julio Cezar de Barros<div>Assistente em Administração</div><div>PIPGEs-UFSCar</div></div></div></div></div></div></div></div></div>